sulfonylureas and insulin may require dose reduction to prevent hypoglycemia when initiating a potent incretin-based agent Discuss realistic titration timelines: patients should understand that therapeutic weight loss at the target dose takes 12 to 20 weeks to become fully apparent Monitoring During Therapy Recheck HbA1c and fasting glucose at 8 and 16 weeks during titration if the patient has type 2 diabetes, as insulin or sulfonylurea doses may need downward adjustment
Injection timing optimization When you take your injection relative to meals affects burping severity
Zhang L, Wu X, Yang R, Chen F, Liao Y, Zhu Z, Wu Z, Sun X, Wang L
A more individualized response-based approach monitors body composition changes and continues therapy as long as positive progress occurs, adjusting or pausing when plateaus develop or goals are achieved
Maintenance Occasional infusions as needed to sustain benefits
An elevated mast cell count in the bladder muscularis was long promoted as a diagnostic histopathologic feature of IC/BPS, and different values for mast cell counts in the detrusor layer were proposed as a diagnostic marker
